Abstract 860
Background
Breast cancer is a major public health problem among women. The use of phytoestrogens like Resveratrol (RSV) has been emerged as a promising chemopreventive and chemotherapeutic agent against breast cancer. However, its effect is reported to be variable according to the administered dose. So this study investigated the underlying mechanisms to the dual action of RSV on estrogen expressing type of breast carcinoma cells (MCF-7).
Methods
MCF-7 cells treated with different low and high doses of RSV and the consequent cytotoxicity, cell cycle, oxidative, angiogenic and inflammatory responses of the cells were evaluated. The autophagic behavior of MCF-7 cells was assessed by RSV combination with autophagic inhibitor (cloroquine). The effect of the combination on cell survival, autophaghic markers expression along with acridine orange staining and cell apoptosis was determined.
Results
Compared to the higher concentration, low dose of RSV (10 µg/ml) exhibited significant anti-survival effect accompanied with cell accumulation at G0/G1phase, higher MDA and VEGF secretion. Concerning the higher doses of RSV (30 and 50 µg/ml), more cells accumulated at S and G2/M phases, and significantly higher levels of GSH, COX-2, PGE2 and nitrate secretion were observed. Autophagic inhibition of RSV exhibited significant acidic lysosomal staining, anti-survival and pro-apoptotic effects on breast carcinoma cells. The combination of low RSV concentration (10 µg/ml) with autophagic inhibitor caused significant decrease in Beclin-1, LC3-B, BCl-2 and MCl-1 expressions, while higher doses of RSV (30 and 50 µg/ml) combination induced Beclin-1, BCl-2 and MCl-1 but reduced LC3-B expressions compared with the single treatment of RSV.
Conclusions
The cytotoxic effect of RSV depends on the autophagic response of breast carcinoma cells in relation to the applied dose.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract